As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.
17 Analysts have issued a Arcturus Therapeutics Ltd forecast:
17 Analysts have issued a Arcturus Therapeutics Ltd forecast:
Jun '25 |
+/-
%
|
||
Revenue | 122 122 |
25%
25%
|
|
Gross Profit | - - |
-
|
|
EBITDA | -69 -69 |
19%
19%
|
EBIT (Operating Income) EBIT | -73 -73 |
19%
19%
|
Net Profit | -60 -60 |
16%
16%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Arcturus Therapeutics Holdings, Inc. engages in the research and development of medical applications for the nucleic acid-focused technology. The firm develops RNA therapeutics which focuses on the treatment of liver and respiratory diseases. Its pipeline include LUNAR-OTC and LUNAR CF. The company was founded in 2013 and is headquartered in San Diego, CA.
Head office | Israel |
CEO | Joseph Payne |
Employees | 175 |
Founded | 2013 |
Website | arcturusrx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.